Archive

HIGHLIGHTS

 
LSP leads €67m [$75m] Series A financing in Alizé Pharma 3
Significantly oversubscribed financing round with an LSP-led international syndicate of investors. Proceeds will be used to grow Alize Ph[...]
 
LSP COMPANY NEWS
LSP portfolio company Binx Health to receive 510(k) marketing authorization for its io- system
 
LSP leads €116m [$133m] financing in AM-Pharma to Conduct Pivotal Phase III Trial...
Financing led by LSP and co-led by Andera Partners, with participation of existing investors Forbion, Ysios Capital, Kurma Partners, ID Invest [...]
 
LSP leads $38.5 Million Series B Financing in DNA Script
Oversubscribed round led by LSP will fund accelerated product development and commercial operations in the U.S.   Paris, May 16, 2019 — [...]
 
LSP leads € 28 million Series B financing in Imcyse
Imcyse raises a total of € 35 million in equity and grants and will use proceeds to facilitate clinical development of it’s technology in type [...]
 
Imcyse gives hope to patients with diabetes and MS
De Tijd - Biotech bedrijf Imcyse biedt hoop aan patiënten met diabetes en MS - Klik hier voor het artikel   De Tijd - Biotech company Im[...]
 
Okairos winner of the Swiss Biotech Success Stories Awards 2018/19
Basel, Switzerland, May 7, 2019 – LSP is pleased to announce that Okairos has been recognised as one of the winners of the Swiss Biotech Success [...]
 
LSP co-leads $50 million Series A financing in SNIPR BIOME
Copenhagen, 11 March 2019 - SNIPR BIOME, a leading CRISPR and microbiome private biotech company incorporated in Copenhagen, Denmark, today announc[...]
 
LSP leads $180 million Series A Financing in Newly-Formed Arvelle Therapeutics
LSP leads one of the largest initial financings for a European biotech company in a global syndicate supporting Arvelle to acquire exclusive rights[...]
 
LSP raises record €750 million in 10 months for life sciences innovations
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY JURISDICTION IN WHICH TO DO SO WOULD CONSTITUT[...]
 
EMA making its first public appearance at our conference
The timing was perfect – the EMA would complete its move to Amsterdam in March and LSP would host its increasingly popular healthcare conference,[...]
 
LSP Life Sciences Fund Performing strongly and ending Q1 2019 up +17.5%
For more insight into our returns and investment strategy please read our just published March Monthly LSP Life Sciences Fund report. To see the fu[...]
 
Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Liste...
Developing Oral Therapies with Best-in-Class Potential Lead Program, IMU-838, Already Advanced into Phase 2 Studies in Ulcerative Colitis[...]
 
LSP IN THE NEWS
LSP on BNR by Marco Groot (around Minute 3:00)
 

2019


Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Proof-of-Concept Clinical Trial of IMU-838 for the Treatment of Patients with Prim...
– Study Being Conducted in Collaboration with Investigators at Arizona State University and the Mayo Clinic –    SAN DIEGO, Aug. 12, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage bi [...]
LSP portfolio company Binx Health to receive 510(k) marketing authorization for its io- system
binx io enables first-ever “test-and-treat” paradigm with sample to answer in 30 minutes for the two most tested-for sexually transmitted infections (STIs)   August 12, 2019 (BOSTON) PR NEWSWIRE – binx [...]
ImCheck Therapeutics Awarded €2 Million from Bpifrance to Advance its First-in-Class Immunotherapy Program into the Clinic
Bpifrance views ImCheck’s projects as unique and well-positioned Marseille, France, August 1, 2019 – ImCheck Therapeutics, a biotech companyon the cutting edge of the next wave of immunotherapies agains [...]
Immunic AG Awarded Research Grant by German Federal Ministry of Education and Research in Support of the InnoMuNiCH Project
SAN DIEGO, Aug. 1, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammator [...]
LSP leads €67m [$75m] Series A financing in Alizé Pharma 3
Significantly oversubscribed financing round with an LSP-led international syndicate of investors. Proceeds will be used to grow Alize Pharma 3’s team in Lyon and Boston, to advance its current programs in [...]
Imcyse gives hope to patients with diabetes and MS
De Tijd - Biotech bedrijf Imcyse biedt hoop aan patiënten met diabetes en MS - Klik hier voor het artikel   De Tijd - Biotech company Imcyse gives hope to patients with diabetes and MS - click here for th [...]


2019
2018
2017
2016
2015
2014
2013
2012
back to news overview
Follow us

Archive

HIGHLIGHTS

 
LSP leads €67m [$75m] Series A financing in Alizé Pharma 3
Significantly oversubscribed financing round with an LSP-led international syndicate of investors. Proceeds will be used to grow Alize Pharma 3’s team in Lyon and Boston, to advance its current programs in[...]
 
LSP COMPANY NEWS
LSP portfolio company Binx Health to receive 510(k) marketing authorization for its io- system
 
LSP leads €116m [$133m] financing in AM-Pharma to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury
Financing led by LSP and co-led by Andera Partners, with participation of existing investors Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthcare Proceeds to[...]
 
LSP leads $38.5 Million Series B Financing in DNA Script
Oversubscribed round led by LSP will fund accelerated product development and commercial operations in the U.S.   Paris, May 16, 2019 — DNA Script today announced an oversubscribed Series B fundraising of $[...]
 
LSP leads € 28 million Series B financing in Imcyse
Imcyse raises a total of € 35 million in equity and grants and will use proceeds to facilitate clinical development of it’s technology in type 1 diabetes, multiple sclerosis and other indications   Liège[...]
 
Imcyse gives hope to patients with diabetes and MS
De Tijd - Biotech bedrijf Imcyse biedt hoop aan patiënten met diabetes en MS - Klik hier voor het artikel   De Tijd - Biotech company Imcyse gives hope to patients with diabetes and MS - click here for th[...]
 
Okairos winner of the Swiss Biotech Success Stories Awards 2018/19
Basel, Switzerland, May 7, 2019 – LSP is pleased to announce that Okairos has been recognised as one of the winners of the Swiss Biotech Success Stories Awards 2018/ 2019.  Okairos (now GlaxoSmithKline) has dev[...]
 
LSP co-leads $50 million Series A financing in SNIPR BIOME
Copenhagen, 11 March 2019 - SNIPR BIOME, a leading CRISPR and microbiome private biotech company incorporated in Copenhagen, Denmark, today announced a $50 million series A financing led by LSP and existing investor L[...]
 
LSP leads $180 million Series A Financing in Newly-Formed Arvelle Therapeutics
LSP leads one of the largest initial financings for a European biotech company in a global syndicate supporting Arvelle to acquire exclusive rights from SK Biopharmaceuticals to develop and commercialize Cenobamate in[...]
 
LSP raises record €750 million in 10 months for life sciences innovations
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY JURISDICTION IN WHICH TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   Succe[...]
 
EMA making its first public appearance at our conference
The timing was perfect – the EMA would complete its move to Amsterdam in March and LSP would host its increasingly popular healthcare conference, BioCapital Europe, in the same month. Having a representative from EM[...]
 
LSP Life Sciences Fund Performing strongly and ending Q1 2019 up +17.5%
For more insight into our returns and investment strategy please read our just published March Monthly LSP Life Sciences Fund report. To see the full report click here. 
 
Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases
Developing Oral Therapies with Best-in-Class Potential Lead Program, IMU-838, Already Advanced into Phase 2 Studies in Ulcerative Colitis and Relapsing-Remitting Multiple Sclerosis Proceeds of approxim[...]
 
LSP IN THE NEWS
LSP on BNR by Marco Groot (around Minute 3:00)
 

2019


Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Proof-of-Concept Clinical Trial of IMU-838 for the Treatment of Patients with Pr...
– Study Being Conducted in Collaboration with Investigators at Arizona State University and the Mayo Clinic –    SAN DIEGO, Aug. 12, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage bi [...]
LSP portfolio company Binx Health to receive 510(k) marketing authorization for its io- system
binx io enables first-ever “test-and-treat” paradigm with sample to answer in 30 minutes for the two most tested-for sexually transmitted infections (STIs)   August 12, 2019 (BOSTON) PR NEWSWIRE – binx [...]
ImCheck Therapeutics Awarded €2 Million from Bpifrance to Advance its First-in-Class Immunotherapy Program into the Clinic
Bpifrance views ImCheck’s projects as unique and well-positioned Marseille, France, August 1, 2019 – ImCheck Therapeutics, a biotech companyon the cutting edge of the next wave of immunotherapies agains [...]
Immunic AG Awarded Research Grant by German Federal Ministry of Education and Research in Support of the InnoMuNiCH Project
SAN DIEGO, Aug. 1, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammator [...]
LSP leads €67m [$75m] Series A financing in Alizé Pharma 3
Significantly oversubscribed financing round with an LSP-led international syndicate of investors. Proceeds will be used to grow Alize Pharma 3’s team in Lyon and Boston, to advance its current programs in [...]
Imcyse gives hope to patients with diabetes and MS
De Tijd - Biotech bedrijf Imcyse biedt hoop aan patiënten met diabetes en MS - Klik hier voor het artikel   De Tijd - Biotech company Imcyse gives hope to patients with diabetes and MS - click here for th [...]


2019
2018
2017
2016
2015
2014
2013
2012
back to news overview